Trial · NCT03259074
Adverse events300
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 300
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | AIN457 150 mg/Placebo | 20 | 286 | |
| other | Diarrhoea | Gastrointestinal disorders | AIN457 300 mg | 22 | 285 | |
| other | Diarrhoea | Gastrointestinal disorders | GP2017 40 mg | 11 | 285 | |
| other | Nasopharyngitis | Infections and infestations | AIN457 150 mg/Placebo | 47 | 286 | |
| other | Nasopharyngitis | Infections and infestations | AIN457 300 mg | 40 | 285 | |
| other | Nasopharyngitis | Infections and infestations | GP2017 40 mg | 44 | 285 | |
| other | Upper respiratory tract infection | Infections and infestations | AIN457 150 mg/Placebo | 17 | 286 | |
| other | Upper respiratory tract infection | Infections and infestations | AIN457 300 mg | 25 | 285 | |
| other | Upper respiratory tract infection | Infections and infestations | GP2017 40 mg | 18 | 285 | |
| other | Ankylosing spondylitis | Musculoskeletal and connective tissue disorders | AIN457 150 mg/Placebo | 11 | 286 | |
| other | Ankylosing spondylitis | Musculoskeletal and connective tissue disorders | AIN457 300 mg | 17 | 285 | |
| other | Ankylosing spondylitis | Musculoskeletal and connective tissue disorders | GP2017 40 mg | 12 | 285 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | AIN457 150 mg/Placebo | 16 | 286 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | AIN457 300 mg | 13 | 285 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | GP2017 40 mg | 12 | 285 | |
| other | Headache | Nervous system disorders | AIN457 150 mg/Placebo | 16 | 286 | |
| other | Headache | Nervous system disorders | AIN457 300 mg | 17 | 285 | |
| other | Headache | Nervous system disorders | GP2017 40 mg | 17 | 285 | |
| other | Hypertension | Vascular disorders | AIN457 150 mg/Placebo | 11 | 286 | |
| other | Hypertension | Vascular disorders | AIN457 300 mg | 11 | 285 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03259074/events